Vision & Projects


Creating Early-Stage Therapeutic Opportunities

One of the primary challenges for clinically-minded academic scientists is the lack of dedicated resources and drug development expertise to transform an early-stage idea or target into a bona fide drug discovery effort. The Novo Broad Greenhouse seeks to empower scientists, by providing funding, drug development know-how, and entrepreneurial guidance from concept to a clinical candidate and beyond.

The Novo Broad Greenhouse seeks to fund dozens of projects over the next several years in a broad variety of therapeutic areas addressing a significant unmet medical need. If successful, graduating projects may form the backbone of a next-generation biotechnology startup, or be taken further into clinical development by a large pharmaceutical company.

Leveraging the Drug Discovery Expertise of the Center for the Development of Therapeutics

Embedded within the Broad Institute, the Center for the Development of Therapeutics (CDoT) translates early-stage academic research into drug-discovery projects, which may potentially lay the foundation for future therapies and potential companies. CDoT leadership has deep drug development expertise, and in its structure and capabilities functions in many ways like a biotech or pharmaceutical company.

The funding provided by Novo Holdings will afford members of the Broad Institute community the opportunity to take advantage of CDoT’s unique capabilities to accelerate a project though the early drug discovery and optimization process, thereby increasing the probability that therapeutic innovation arising from a project can eventually reach patients suffering from disease.

Current Projects

Current drug-discovery projects in the Novo Broad Greenhouse focus on bladder cancer, immuno-oncology, and solid tumors.